Reviews:
Type I insulinlike growth factor receptor signaling in hematological malignancies
PDF | Full Text | How to cite
Metrics: PDF 3540 views | Full Text 7612 views
Deeksha Vishwamitra1, Suraj Konnath George1, Ping Shi2, Ahmed O. Kaseb3 and Hesham M. Amin1,4
1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China
3 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA
Correspondence to:
Hesham M. Amin, email:
Keywords: IGF-IR; plasma cell myeloma; leukemia; lymphoma
Received: January 21, 2016 Accepted: September 12, 2016 Published: September 19, 2016
Abstract
The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss current understanding of the role of IGF-IR signaling in cancer with a focus on the hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.